Dyne Therapeutics gains FDA Priority Review for DMD drug z-rostudirsen
Dyne Therapeutics has received FDA acceptance and Priority Review for its Biologics License Application for z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy patients amenable to exon 51 skipping. The PDUFA target action date is set for 21 January 2027, and the Waltham, Massachusetts-based company says it expects a potential US commercial launch in the first quarter of that year, should approval be received on schedule.
The announcement came alongside the company's second-quarter 2026 financial results. R&D expenses rose sharply to $152.2 million in Q2 2026, up from $99.2 million in Q2 2025, driven largely by manufacturing scale-up and clinical costs for z-rostudirsen and its DM1 candidate z-basivarsen. G&A expenses reached $29.5 million, nearly double the $16.6 million recorded in the comparable period a year earlier, as the company invests in commercial readiness infrastructure ahead of a potential launch.
Pipeline progress across three programmes
Beyond the near-term DMD milestone, Dyne reported meaningful progress across its portfolio. Enrolment of 71 participants in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) was completed in June 2026. Topline data from that cohort are planned for Q1 2027, which the company intends to use to support a BLA submission under the FDA's Accelerated Approval pathway in Q3 2027. A potential US launch of z-basivarsen is targeted for H1 2028, contingent on Priority Review being granted and approval following on the anticipated timeline. Dyne also commenced dosing in the global confirmatory Phase 3 HARMONIA trial of z-basivarsen in July 2026.
A third programme received an IND clearance from the FDA in July 2026. DYNE-302, targeting facioscapulohumeral muscular dystrophy (FSHD), will enter a randomised, placebo-controlled Phase 1 trial assessing safety and tolerability, as well as pharmacodynamic markers including muscle DUX4 transcriptome levels. All three clinical candidates deploy the company's proprietary FORCE platform, which is designed to selectively deliver oligonucleotide therapies to muscle tissue.
John Cox, president and chief executive, said the FDA's acceptance of the BLA represented "a defining step in Dyne's evolution toward becoming a commercial-stage company."
Financial position and competitive context
Dyne closed Q2 2026 with $898.5 million in cash, cash equivalents and marketable securities. A subsequent underwritten public offering of approximately 21 million shares at $20.50 each raised estimated net proceeds of around $405 million, lifting the combined balance well above $1.3 billion. The company now expects its cash position to fund operations into Q2 2028.
The neuromuscular disease space has grown increasingly active. Sarepta Therapeutics, which markets the approved exon 51 skipping therapy eteplirsen as well as the more recently approved golodirsen and casimersen for adjacent exon targets, remains the dominant commercial incumbent in DMD. Sarepta's gene therapy SRP-9001 (delandistrogene moxeparvovec) adds a further layer of competition across the broader DMD landscape. Dyne is positioning z-rostudirsen as differentiated on the basis of its FORCE delivery platform, which it argues enables superior muscle uptake compared with first-generation phosphorodiamidate morpholino oligomer approaches. How regulators and clinicians weigh that pharmacological case against the established exon-skipping alternatives will be a key question as the PDUFA date approaches.
With three programmes now in the clinic, a near-term regulatory decision on its lead asset, and a strengthened balance sheet, Dyne's near-term milestones are unusually well-defined for a company still in the clinical stage.